
## Tomas Castro-Dopico

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5728837/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis. Immunity, 2019, 50, 1099-1114.e10.	14.3	139
2	Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis. Proceedings of the United States of America, 2020, 117, 15160-15171.	7.1	90
3	lgG and FcÎ <sup>3</sup> Receptors in Intestinal Immunity and Inflammation. Frontiers in Immunology, 2019, 10, 805.	4.8	85
4	GM-CSF Calibrates Macrophage Defense and Wound Healing Programs during Intestinal Infection and Inflammation. Cell Reports, 2020, 32, 107857.	6.4	79
5	Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nature Medicine, 2022, 28, 766-779.	30.7	70
6	Cytokine absorption during human kidney perfusion reduces delayed graft function–associated inflammatory gene signature. American Journal of Transplantation, 2021, 21, 2188-2199.	4.7	38
7	Targeting B cells for inflammatory bowel disease treatment: back to the future. Current Opinion in Pharmacology, 2020, 55, 90-98.	3.5	34
8	B cell class switching in intestinal immunity in health and disease. Scandinavian Journal of Immunology, 2022, 95, e13139.	2.7	21
9	FcÎ <sup>3</sup> Receptors in Solid Organ Transplantation. Current Transplantation Reports, 2016, 3, 284-293.	2.0	17
10	Interaction of lipids with the neurotensin receptor 1. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 1278-1287.	2.6	15
11	Mucosal IgG in inflammatory bowel disease – a question of (sub)class?. Gut Microbes, 2020, 12, 1651596.	9.8	14
12	Group 3 innate lymphocytes make a distinct contribution to type 17 immunity in bladder defence. IScience, 2022, 25, 104660.	4.1	8
13	The Immunology of Transplantation. , 2019, , 9-35.		0
14	169 A PATHOGENIC B CELL RESPONSE IN ULCERATUVE COLITIS THAT ASSOCIATES WITH TREATMENT RESISTANCE AND DISEASE COMPLICATIONS. Gastroenterology, 2021, 160, S-41.	1.3	0